Clinical activity of a new regimen combining gemcitabine and alemtuzumab in high‐risk relapsed/refractory chronic lymphocytic leukemia patients
暂无分享,去创建一个
G. Laurent | C. Récher | L. Obéric | L. Ysebaert | B. Hébraud | E. Suc | P. Houyau | W. Vaillant
[1] A. Zelenetz,et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. , 2014, The New England journal of medicine.
[2] Juthamas Sukbuntherng,et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. , 2013, The New England journal of medicine.
[3] F. Rodeghiero,et al. The combination of rituximab, bendamustine, and cytarabine for heavily pretreated relapsed/refractory cytogenetically high‐risk patients with chronic lymphocytic leukemia , 2013, American journal of hematology.
[4] J. Neffendorf,et al. Ibrutinib in relapsed chronic lymphocytic leukemia. , 2013, The New England journal of medicine.
[5] A. Pettitt,et al. Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] J. Gribben,et al. Risk categories and refractory CLL in the era of chemoimmunotherapy. , 2012, Blood.
[7] M. Hallek,et al. Alemtuzumab for patients with chronic lymphocytic leukaemia. , 2012, The Cochrane database of systematic reviews.
[8] R. Foà,et al. An Italian retrospective study on the routine clinical use of low‐dose alemtuzumab in relapsed/refractory chronic lymphocytic leukaemia patients , 2012, British journal of haematology.
[9] M. Hallek,et al. Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial. , 2011, The Lancet. Oncology.
[10] H. Döhner,et al. Alemtuzumab Plus Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allogeneic Transplantation in Ultra High-Risk CLL: Updated Results From a Phase II Study of the Gcllsg and fcgcll/MW , 2011 .
[11] W. Wierda,et al. Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study. , 2011, Blood.
[12] V. Petrizzi,et al. Clinical Trials and Observations , 2022 .
[13] R. Greil,et al. Clinical outcome of pretreated B-cell chronic lymphocytic leukemia following alemtuzumab therapy: a retrospective study on various cytogenetic risk categories. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] Michael Hallek,et al. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. , 2009, Blood.
[15] R. Schlenk,et al. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] T. Kipps,et al. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] H. Kantarjian,et al. The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy , 2007, Leukemia & lymphoma.
[18] R. Greil,et al. Routine clinical use of alemtuzumab in patients with heavily pretreated B‐cell chronic lymphocytic leukemia , 2006, Cancer.
[19] H. Döhner,et al. Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. , 2002, The New England journal of medicine.
[20] J. Byrd,et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. , 2002, Blood.
[21] G. Salles,et al. Gemcitabine as a single agent in the treatment of relapsed or refractory low‐grade non‐Hodgkin's lymphoma , 2001, British journal of haematology.
[22] M. Grever,et al. Gemcitabine demonstrates in vitro activity against human B-cell chronic lymphocytic leukemia. , 2001, Leukemia research.
[23] A Benner,et al. Genomic aberrations and survival in chronic lymphocytic leukemia. , 2000, The New England journal of medicine.
[24] W. Hiddemann,et al. Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] S. Allerheiligen,et al. Preclinical, pharmacologic, and phase I studies of gemcitabine. , 1997, Seminars in oncology.
[26] D. Carson,et al. Quantitative immunoassay of human deoxycytidine kinase in malignant cells. , 1992, Analytical biochemistry.